Host: The Japanese Society of Toxicology
Viral infections are a common topic in our daily lives. Since clinical trials of antiviral drugs cannot be conducted in pregnant women, most drug package inserts state risks to pregnant women based on results of nonclinical reproductive and developmental toxicity studies. The teratogenic potential of Avigan was reported in the general media due to people's interest in COVID-19 therapeutic medicines. In this session, I would like to introduce the contents of the drug package insert and the reproductive toxicity of antiviral drugs, based on publicly available information.
